RxDoctor Payments Data

Monica Aloman, MD

Rheumatology · Chicago, ILNPI 1134236789

Payments from drug & device makers

$11,271in general payments, 2019–2025

Across 474 payments — averaging $23.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Amgen$2K
  • AstraZeneca$1K
  • Johnson & Johnson$847
  • GSK$621
  • Novartis$563
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$11,15799%
  • Education$1141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,271 in reported general payments places this provider in the 75th percentile of 287 rheumatology providers in Illinois.

See all rheumatology providers in Illinois

Medicare billing

Part B allowed, 2024
$482,229
Medicare patients
384
Services billed
22,882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept18$139,611
Humira(Cf) PenAdalimumab16$118,917
RinvoqUpadacitinib14$94,767
Xeljanz XrTofacitinib Citrate11$88,901
OtezlaApremilast17$85,813
Humira(Cf)Adalimumab12$82,813
Hydroxychloroquine Sulfate202$7,074
Mycophenolate Mofetil24$6,246
Leflunomide91$6,058
Cevimeline Hcl24$4,110
MethotrexateMethotrexate Sodium143$3,611
Sulfasalazine DrSulfasalazine30$1,972
Colchicine15$1,713
Prednisone177$1,437
Gabapentin90$1,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$3,171$177,58026 claims
AmgenOtezla$1,816$85,81317 claims
Scilex Pharmaceuticals Inc.Colchicine$24$1,71315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 287 rheumatology providers in Illinois.

Other rheumatology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →